139 related articles for article (PubMed ID: 23822603)
1. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).
Sandhaus RA; Stocks J; Rouhani FN; Brantly M; Strauss P
COPD; 2014 Feb; 11(1):17-25. PubMed ID: 23822603
[TBL] [Abstract][Full Text] [Related]
2. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
3. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
4. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the liquid and lyophilized formulations of Prolastin®-C for Alpha
Arora V; Cruz M; Lang J; Klos AM; Merritt WK; Price J; Taylor G; Vandeberg P; Wee K; Willis T
Biologicals; 2019 Nov; 62():77-84. PubMed ID: 31522909
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Biochemical Efficacy of an α
Li Z; Franke RM; Morris DN; Yel L
Pulm Ther; 2022 Sep; 8(3):311-326. PubMed ID: 36001294
[TBL] [Abstract][Full Text] [Related]
7. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
[TBL] [Abstract][Full Text] [Related]
8. Alpha 1-antitrypsin augmentation therapy.
Sandhaus RA
Agents Actions Suppl; 1993; 42():97-102. PubMed ID: 8356934
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of a Liquid Formulation of Alpha
Barker AF; Campos MA; Brantly ML; Stocks JM; Sandhaus RA; Lee D; Steinmann K; Lin J; Sorrells S
COPD; 2017 Dec; 14(6):590-596. PubMed ID: 28985109
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
Campos MA; Kueppers F; Stocks JM; Strange C; Chen J; Griffin R; Wang-Smith L; Brantly ML
COPD; 2013 Dec; 10(6):687-95. PubMed ID: 23862647
[TBL] [Abstract][Full Text] [Related]
12. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.
Kolarich D; Turecek PL; Weber A; Mitterer A; Graninger M; Matthiessen P; Nicolaes GA; Altmann F; Schwarz HP
Transfusion; 2006 Nov; 46(11):1959-77. PubMed ID: 17076852
[TBL] [Abstract][Full Text] [Related]
13. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.
Stocks JM; Brantly M; Pollock D; Barker A; Kueppers F; Strange C; Donohue JF; Sandhaus R
COPD; 2006 Mar; 3(1):17-23. PubMed ID: 17175661
[TBL] [Abstract][Full Text] [Related]
14. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
Louie SG; Sclar DA; Gill MA
Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
[TBL] [Abstract][Full Text] [Related]
15. Biochemical comparison of four commercially available human α
Boerema DJ; An B; Gandhi RP; Papineau R; Regnier E; Wilder A; Molitor A; Tang AP; Kee SM
Biologicals; 2017 Nov; 50():63-72. PubMed ID: 28882403
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Stocks JM; Brantly ML; Wang-Smith L; Campos MA; Chapman KR; Kueppers F; Sandhaus RA; Strange C; Turino G
BMC Clin Pharmacol; 2010 Sep; 10():13. PubMed ID: 20920295
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency.
Li Z; Gaurav M; Yel L
Pulm Pharmacol Ther; 2023 Dec; 83():102265. PubMed ID: 37923165
[TBL] [Abstract][Full Text] [Related]
18. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.
Stoller JK; Rouhani F; Brantly M; Shahin S; Dweik RA; Stocks JM; Clausen J; Campbell E; Norton F
Chest; 2002 Jul; 122(1):66-74. PubMed ID: 12114340
[TBL] [Abstract][Full Text] [Related]
19. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
20. [Practical applications of recombinant alpha-1-antitrypsin in medicine].
Kabziński J; Kedziora J; Majsterek I
Pol Merkur Lekarski; 2010 Dec; 29(174):345-50. PubMed ID: 21298982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]